Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss
The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Yuxia Wei, PhD
- Telefonnummer: 86-18813185223
- E-post: 2026020052@hust.edu.cn
Studer Kontakt Backup
- Navn: An Pan, PhD
- Telefonnummer: 86-18186123783
- E-post: panan@hust.edu.cn
Studiesteder
-
-
Hubei
-
Enshi, Hubei, Kina
- The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
-
Shiyan, Hubei, Kina
- Sinopharm Dongfeng General Hospital
-
Wuhan, Hubei, Kina
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, Hubei, Kina
- Huazhong University of Science and Technology
-
Ta kontakt med:
- Yuxia Wei, PhD
- Telefonnummer: 86-18813185223
- E-post: 2026020052@hust.edu.cn
-
Ta kontakt med:
- An Pan, PhD
- E-post: panan@hust.edu.cn
-
Xiangyang, Hubei, Kina
- Xiangyang No.1 People's hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion criteria:
Be overweight or obese (meeting any of the following criteria):
- Obesity: BMI >=28 kg/m²;
- Overweight (BMI >= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease.
- Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months.
- Age 18-64 years.
- Consent to participate and sign the informed consent form.
Exclusion criteria:
- Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months;
- Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt);
- Be allergic or intolerance to inulin-type substances;
- Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials;
- Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding;
- Deemed unsuitable for participation by the investigator's judgment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: inulin (prebiotics)
The intervention dose is 10 grams per day.
The intervention will last for 4 months.
|
The intervention dose is 10 grams per day.
The intervention will last for 4 months.
|
|
Placebo komparator: maltodextrin
The intake dose is 10 grams per day for 4 months.
|
The dose is 10 grams per day for 4 months.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
change in concentrations of blood lipid levels in millimole per liter (mmol/L).
Tidsramme: From enrollment to the end of intervention at 4 months
|
change in total cholesterol and triglycerides levels from baseline to 4-month visit.
The values will be reported in mmol/L.
|
From enrollment to the end of intervention at 4 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
change in frequency of gastrointestinal symptoms
Tidsramme: From enrollment to the end of intervention at 4 months
|
change in frequency of gastrointestinal symptoms such as diarrhea and constipation baseline to 4-month visit
|
From enrollment to the end of intervention at 4 months
|
|
change in concentration of glycosylated Hemoglobin A1c (HbA1c) in millimoles per mole (mmol/mol)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Description: change in concentration of glycosylated Hemoglobin A1c (HbA1c) from baseline to 4-month visit.
The values will be reported in mmol/mol.
|
From enrollment to the end of intervention at 4 months
|
|
change in level of insulin resistance
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in HOMA-IR (homeostatic model assessment of insulin resistance) and adipo-IR (adipose tissue insulin resistance index) from baseline to 4-month visit.
HOMA-IR will be calculated based on fasting glucose (mmol/L) and fasting insulin (mIU/L).
Adipo-IR will be estimated using fasting insulin (mIU/L) and fasting free fatty acids (mmol/L).
|
From enrollment to the end of intervention at 4 months
|
|
change in body weight in kilograms (kg)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in body weight (kg) from baseline to 4-month visit
|
From enrollment to the end of intervention at 4 months
|
|
change in body fat percentage (%)
Tidsramme: From enrollment to the end of intervention at 4 months
|
change in body fat percentage from baseline to 4-month visit.
The values will be reported in percentage (%).
|
From enrollment to the end of intervention at 4 months
|
|
change in waist circumference in centimeters (cm)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in waist Circumference (cm) from baseline to the 4-month visit.
|
From enrollment to the end of intervention at 4 months
|
|
change in level of gut microbiota abundance
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in gut microbiota abundance from baseline to 4-month visit
|
From enrollment to the end of intervention at 4 months
|
|
change in level of gut microbiota diversity
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in gut microbiota alpha and beta diversity from baseline to 4-month visit.
|
From enrollment to the end of intervention at 4 months
|
|
change in estimated glomerular filtration rate (eGFR) in milliliter per minute per 1.73 square meters (mL/min/1.73 m²)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in estimated glomerular filtration rate (eGFR) from baseline to the 4-month visit.
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI ) (2009) method will be used to estimate eGFR value.
The value is reported in milliliter per minute per 1.73 square meters (mL/min/1.73
m²).
|
From enrollment to the end of intervention at 4 months
|
|
change in concentrations of liver function markers in units per liter (U/L)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) from baseline to the 4-month visit.
These values are reported in units per liter (U/L).
|
From enrollment to the end of intervention at 4 months
|
|
change in level of C-reactive protein (CRP) in milligram per liter (mg/L)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in C-reactive protein (CRP) from baseline to the 4-month visit.
The value is reported in milligram per liter (mg/L).
|
From enrollment to the end of intervention at 4 months
|
|
change in blood pressure in millimeters of mercury (mmHg)
Tidsramme: From enrollment to the end of intervention at 4 months
|
Change in systolic and diastolic blood pressure from baseline to the 4-month visit.
The values are reported in millimeters of mercury (mmHg).
|
From enrollment to the end of intervention at 4 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: An Pan, Huazhong University of Science and Technology
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Ernæringsforstyrrelser
- Overernæring
- Kroppsvekt
- Endringer i kroppsvekt
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvektig
- Overvekt
- Vekttap
- Kosttilskudd
- Mat
- Kosthold, mat og ernæring
- Fysiologiske fenomener
- Mat og drikke
- Kostholdskarbohydrater
- Karbohydrater
- Polymerer
- Makromolekylære stoffer
- Polysakkarider
- Stivelse
- Glukaner
- Biopolymerer
- Fruktaner
- Kostholdsfiber
- Polysakkarider, bakterie
- Inulin
- Prebiotika
Andre studie-ID-numre
Andre studie-ID-numre
- Prebiotics in GLP-1 RA users
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .